Publications

Search or filter publications

Search publications Search

Filter by type:

Filter by publication type

• Book
• Book chapter
• Conference paper
• Journal article
• Other
• Patent
• Poster
• Report
• Scholarly edition
• Software
• Thesis dissertation
• Working paper

Filter by year:

Filter from 20252024202320222021202020192018201720162015201420132012201120102009200820072006200520042003200220012000199919981997199619951994199319921991199019891988198719861985198419831982198119801979197819771976 to Filter to 20252024202320222021202020192018201720162015201420132012201120102009200820072006200520042003200220012000199919981997199619951994199319921991199019891988198719861985198419831982198119801979197819771976

---

Search results

• Journal article
  Polineni D, Davies JC, Boyd AC, Donaldson SH, Gill DR, Griesenbach U, Hyde SC, Jain R, McLachlan G, Mall MA, Alton EWFWet al., 2025,

  Potential gene therapies for cystic fibrosis: a plain language summary for non-specialists and the lay community

  , Future Rare Diseases, Vol: 5
  • Publisher Web Link
  • Cite
• Journal article
  Sanchez-Garcia MA, Sadiku P, Ortmann BM, Wit N, Negishi Y, Coelho P, Zhang A, Pednekar C, Howden AJM, Griffith DM, Seear R, Kindrick JD, Mengede J, Cooper G, Morrison T, Watts ER, Shimeld BT, Reyes L, Mirchandani AS, Arienti S, Xu X, Thomson A, Brenes AJ, Turton HA, Dowey R, Hull RC, Davidson-Smith H, Mclaren A, Deans A, Choudhury G, Doverman K, Hope D, Vick O, Woodhead A, Petrie I, Green S, Rzechorzek NM, Turtle L, Openshaw PJM, Semple MG, Sproul D, Baillie JK, Thompson AAR, Mole DR, von Kriegsheim A, Whyte MKB, Mhlanga MM, Nathan JA, Walmsley SRet al., 2025,

  Hypoxia induces histone clipping and H3K4me3 loss in neutrophil progenitors resulting in long-term impairment of neutrophil immunity (vol 26, 1903, 2025)

  , NATURE IMMUNOLOGY, ISSN: 1529-2908
  • Cite
• Journal article
  Shaaban FL, Groenendijk RW, Baral R, Caballero MT, Crowe JE, Englund JA, Esteban I, Hirve S, Jit M, Kalergis AM, Karron RA, Lukacs N, Martinon-Torres F, Mejias A, Nair H, Nisar MI, Nyiro JU, Pecenka C, Sparrow E, Srikantiah P, Thwaites RS, Zar HJ, Bont LJet al., 2025,

  The path to equitable respiratory syncytial virus prevention for infants: challenges and opportunities for global implementation

  , The Lancet Global Health, Vol: 13, Pages: e2165-e2174, ISSN: 2214-109X

  The approval for a respiratory syncytial virus (RSV) maternal vaccination programme by Gavi, The Vaccine Alliance, marks substantial progress toward equitable access, with important work still to come. Several countries, most of which are high-income, have introduced RSV immunisation either using a vaccine containing the RSV fusion protein in its prefusion conformation, which is given to pregnant people in late pregnancy, or by using a long-acting monoclonal antibody (mAb) administered directly to infants. Post-implementation real-world effectiveness data show a major impact in reducing medically attended RSV-lower respiratory tract illness and hospitalisation using either strategy. Although RSV poses a substantial burden to infants and vulnerable children worldwide, 97% of associated mortality occurs in low-income and middle-income countries. However, few of these countries have authorised and introduced RSV preventive strategies. This Review outlines the challenges and opportunities for expanding access to RSV prevention for infants in resource-restricted settings guided by WHO's Immunization Agenda 2030 and the UN's Leave No One Behind framework for non-discriminatory sustainable development. We discuss burden, vaccine and mAb development, health economics and impact modelling, policy, implementation and programmatic considerations, surveillance, and awareness as key RSV domains. This Review summarises recent advances in research and highlights the urgent steps needed to ensure equitable access to RSV prevention for all infants worldwide.

  • Abstract
  • Publisher Web Link
  • Cite
• Journal article
  Griesenbach U, McLachlan G, Sinadinos A, Cheminay C, Ashour J, Cox J, Schwotzer D, Vyhnal K, Gupta A, Chan M, Meng C, Pineault K, Castells E, Dean RJ, Viegas MA, Boyd AC, Davies JC, Gill DR, Hyde SC, Blanset D, Alton EWFWet al., 2025,

  F/HN-pseudotyped lentiviral vector efficiently transduces non-human primate airways with no evidence of relevant toxicity

  , Molecular Therapy Advances, Pages: 201655-201655, ISSN: 3117-387X
  • Publisher Web Link
  • Cite
• Journal article
  Mayer-Hamblett N, Kerper NR, Clancy JP, Davies JC, Taylor-Cousar JL, Donaldson SH, Bell SC, Jain R, Simmonds NJ, Mall MA, Goss CH, Rayment JH, Setiawan L, Pilewski JMet al., 2025,

  Maximising opportunity for therapeutic success: sequential participation in cystic fibrosis nucleic acid-based therapy trials

  , LANCET RESPIRATORY MEDICINE, Vol: 13, ISSN: 2213-2600
  • Cite
• Journal article
  Cabug AF, Crawford JC, Mcquilten HA, Foo IJH, Allen LF, Gebregzabher D, Mettelman RC, Novak T, Chou J, Rowntree LC, Hagen RR, Thomson AJ, Martin GE, Gilbertson B, Souter MN, James F, Goodall E, Rizzetto S, Flerlage T, Jia X, Van de Velde L-A, Chang SY, Luciani F, Thwaites RS, Trubiano JA, Kotsimbos TC, Cheng AC, Randolph AG, Thomas PG, Xu J, Wang Z, Nguyen THO, Chua BY, Kedzierski L, Kedzierska Ket al., 2025,

  High expression of interleukin-18 receptor alpha correlates with severe respiratory viral disease and defines T cells with reduced cytotoxic signatures

  , NATURE COMMUNICATIONS, Vol: 16
  • Cite
• Journal article
  Chiu C, 2025,

  Pre-existing and early cellular immune factors correlate with functionally complete protection against primary controlled human SARS-CoV-2 infection

  , Nature Communications, ISSN: 2041-1723

  Identifying host factors that mediate protection during first exposure to newly emergent viruses may assist in responding to future pandemics. Here, we report correlates of protection in a controlled human infection model of SARS-CoV-2 in serologically naïve individuals (n=34, aged 18-29 years) inoculated with 10 TCID50 of a D614G-containing pre-Alpha variant SARS-CoV-2. Eighteen developed “sustained infection” and seroconverted, while the remaining 16 did not. Pre-exposure and early immune factors associated with resisting infection were comprehensively analysed using multiplex protein, cytometric and RNA sequencing approaches in the upper respiratory mucosa and circulation. Associations between pre-existing antibody level and outcome suggested a modest role for cross-reactive antibodies in protection, with baseline nasal anti-SARS-CoV-2 Spike IgM levels correlating with delayed infection onset. Instead, resistance to infection was associated with heightened nasopharyngeal CCL13 levels produced locally by conventional dendritic cells and monocytes. Cross-reactive IL-2 producing T cells against SARS-CoV-2 non-structural proteins and less differentiated NK cells were also enriched at the time of inoculation in these individuals. This was followed by increased numbers of innate and adaptive cellsin the nasopharynx, including resident memory T cells, within 24 hours of virus exposure. Conditional independence network analysis revealed nasal CCL13 as the central node in a module associated with protection, connected to pre-existing RTC-specific T cells by CD1c+ DCs. In those who became infected, higher baseline cross-reactive T cell and less differentiated NK cell frequencies also correlated with shorter duration of infection. Thus, enhanced pre-existing mucosal chemokine levels may enable rapid immune cell recruitment and antigen-presentation to resident T cells in respiratory mucosa, effectively blocking infection. Where this local response fails to c

  • Abstract
  • Cite
• Journal article
  Szentpetery S, Riva D, Blumenfeld YJ, Engelhardt JF, Luna-Paredes C, Milla C, Schneider-Futschik EK, Sheffield JS, Darrah R, Davies JC, Flume PA, Foil KE, Fortner CN, Guimbellot JS, Lyerly AD, Mayer-Hamblett N, Ren CL, Spano J, Tillman EM, Trimble A, Wilfond BS, Taylor-Cousar JLet al., 2025,

  PRenatal mOdulator treatment to PrEvent CF complicaTions (PROTECT) workshop report

  , JOURNAL OF CYSTIC FIBROSIS, Vol: 24, Pages: 1058-1066, ISSN: 1569-1993
  • Cite
• Journal article
  Sanchez-Garcia MA, Sadiku P, Ortmann BM, Wit N, Negishi Y, Coelho P, Zhang A, Pednekar C, Howden AJM, Griffith DM, Seear R, Kindrick JD, Mengede J, Cooper G, Morrison T, Watts ER, Shimeld BT, Reyes L, Mirchandani AS, Arienti S, Xu X, Thomson A, Brenes AJ, Turton HA, Dowey R, Hull RC, Davidson-Smith H, McLaren A, Deans A, Choudhury G, Doverman K, Hope D, Vick O, Woodhead A, Petrie I, Green S, Rzechorzek NM, Turtle L, Openshaw PJM, Semple MG, Sproul D, Baillie JK, Thompson AAR, Mole DR, Von Kriegsheim A, Whyte MKB, Mhalanga MM, Nathan JA, Walmsley SRet al., 2025,

  Hypoxia induces histone clipping and H3K4me3 loss in neutrophil progenitors resulting in long-term impairment of neutrophil immunity

  , NATURE IMMUNOLOGY, Vol: 26, ISSN: 1529-2908
  • Cite
  • Citations: 1
• Journal article
  Wainwright C, McColley SA, McNally P, Powers M, Ratjen F, Rayment JH, Retsch-Bogart G, Roesch E, Ramsey B, Mckone EF, Tullis E, Mall MA, Taylor-Cousar JL, Waltz D, Ahluwalia N, Chu C, Scirica C, Davies JCet al., 2025,

  Long-Term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Children ≥6 Years with Cystic Fibrosis and at Least One <i>F508del</i> Allele: A 192-Week, Phase 3, Open-Label Extension Study

  , AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, Vol: 211, Pages: 1915-1925, ISSN: 1073-449X
  • Cite
  • Citations: 2

This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.